T2EVOLVE

The aim of the project T2EVOLVE is to build a sustainable innovation ecosystem that will support the development of advance engineered T cell therapy to a level where every European cancer patient in need has access to safe and effective T cell products. How? The optimization of preclinical models, analytical monitoring, lymphodepletion regimens will enhance the development of safer and more effective engineered T cell therapies by reducing the toxicity observed in clinical trials and improve the success rate of clinical trials. A strategic aim of the project is to take an advantage on the tremendous potential that exists in Europe and close the gap in clinical and commercial translation in order to bring the EU back to the forefront of this global movement.

ECPC will assist the T2EVOLVE project by engaging in patient involvement in the R&D process, co-development of patient friendly communication tools to improve the patient journey (M4-60)
co-development of tools and materials to help HCPs better respond to patient needs, patient-centered Health Technology Assessment of engineered T cell therapy and the creation of a roadmap for engineered T-cell therapy (online white paper).